65 related articles for article (PubMed ID: 17467924)
1. Postimplant dosimetry using a Monte Carlo dose calculation engine: a new clinical standard.
Carrier JF; D'Amours M; Verhaegen F; Reniers B; Martin AG; Vigneault E; Beaulieu L
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1190-8. PubMed ID: 17467924
[TBL] [Abstract][Full Text] [Related]
2. Investigation of interseed attenuation and tissue composition effects in (125)I seed implant prostate brachytherapy.
Mason J; Al-Qaisieh B; Bownes P; Henry A; Thwaites D
Brachytherapy; 2014; 13(6):603-10. PubMed ID: 24913435
[TBL] [Abstract][Full Text] [Related]
3. Monte Carlo investigation of I-125 interseed attenuation for standard and thinner seeds in prostate brachytherapy with phantom validation using a MOSFET.
Mason J; Al-Qaisieh B; Bownes P; Henry A; Thwaites D
Med Phys; 2013 Mar; 40(3):031717. PubMed ID: 23464312
[TBL] [Abstract][Full Text] [Related]
4. Large-scale Retrospective Monte Carlo Dosimetric Study for Permanent Implant Prostate Brachytherapy.
Miksys N; Vigneault E; Martin AG; Beaulieu L; Thomson RM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):606-615. PubMed ID: 28126308
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric and radiobiological investigation of permanent implant prostate brachytherapy based on Monte Carlo calculations.
Haidari AM; Miksys N; Soubiran P; Cygler JE; Holmes O; Perry G; Thomson RM
Brachytherapy; 2019; 18(6):875-882. PubMed ID: 31400953
[TBL] [Abstract][Full Text] [Related]
6. Impact of interseed attenuation and tissue composition for permanent prostate implants.
Carrier JF; Beaulieu L; Therriault-Proulx F; Roy R
Med Phys; 2006 Mar; 33(3):595-604. PubMed ID: 16878563
[TBL] [Abstract][Full Text] [Related]
7. Quantifying the effect of seed orientation in postplanning dosimetry of low-dose-rate prostate brachytherapy.
Collins Fekete CA; Plamondon M; Martin AG; Vigneault É; Verhaegen F; Beaulieu L
Med Phys; 2014 Oct; 41(10):101704. PubMed ID: 25281943
[TBL] [Abstract][Full Text] [Related]
8. CT-based dosimetry calculations for 125I prostate implants.
DeMarco JJ; Smathers JB; Burnison CM; Ncube QK; Solberg TD
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1347-53. PubMed ID: 10613332
[TBL] [Abstract][Full Text] [Related]
9. A Monte Carlo study on the effect of seed design on the interseed attenuation in permanent prostate implants.
Afsharpour H; D'Amours M; Coté B; Carrier JF; Verhaegen F; Beaulieu L
Med Phys; 2008 Aug; 35(8):3671-81. PubMed ID: 18777927
[TBL] [Abstract][Full Text] [Related]
10. Comparison of intraoperative ultrasound with postimplant computed tomography--dosimetric values at Day 1 and Day 30 after prostate brachytherapy.
Ohashi T; Yorozu A; Toya K; Saito S; Momma T; Nagata H; Kosugi M; Shigematsu N; Kubo A
Brachytherapy; 2007; 6(4):246-53. PubMed ID: 17959425
[TBL] [Abstract][Full Text] [Related]
11. Brachytherapy in patients with small prostate glands.
Loblaw DA; Wallner K; Dibiase S; Russell K; Blasko J; Ellis W
Tech Urol; 2000 Jun; 6(2):64-9. PubMed ID: 10798802
[TBL] [Abstract][Full Text] [Related]
12. MCPI: a sub-minute Monte Carlo dose calculation engine for prostate implants.
Chibani O; Williamson JF
Med Phys; 2005 Dec; 32(12):3688-98. PubMed ID: 16475768
[TBL] [Abstract][Full Text] [Related]
13. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
14. Comparison of real-time intraoperative ultrasound-based dosimetry with postoperative computed tomography-based dosimetry for prostate brachytherapy.
Nag S; Shi P; Liu B; Gupta N; Bahnson RR; Wang JZ
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):311-7. PubMed ID: 17996395
[TBL] [Abstract][Full Text] [Related]
15. Dosimetric comparison of interactive planned and dynamic dose calculated prostate seed brachytherapy.
Meijer GJ; van den Berg HA; Hurkmans CW; Stijns PE; Weterings JH
Radiother Oncol; 2006 Sep; 80(3):378-84. PubMed ID: 16930753
[TBL] [Abstract][Full Text] [Related]
16. Tissue composition and density impact on the clinical parameters for (125)I prostate implants dosimetry.
Oliveira SM; Teixeira NJ; Fernandes L; Teles P; Vieira G; Vaz P
Phys Med; 2014 Nov; 30(7):799-808. PubMed ID: 25239870
[TBL] [Abstract][Full Text] [Related]
17. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy.
Stone NN; Hong S; Lo YC; Howard V; Stock RG
Brachytherapy; 2003; 2(1):17-25. PubMed ID: 15062159
[TBL] [Abstract][Full Text] [Related]
18. On the sensitivity of α/β prediction to dose calculation methodology in prostate brachytherapy.
Afsharpour H; Walsh S; Collins Fekete CA; Vigneault E; Verhaegen F; Beaulieu L
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):345-50. PubMed ID: 24411607
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
Potters L; Calugaru E; Jassal A; Presser J
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
[TBL] [Abstract][Full Text] [Related]
20. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy.
Wallner K; Roy J; Harrison L
Int J Radiat Oncol Biol Phys; 1995 May; 32(2):465-71. PubMed ID: 7751187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
